WASHINGTON - President Donald Trump signed an executive order Monday directing the National Institutes of Health to establish a dedicated women's health division within 90 days, placing conditions that affect women throughout their lives at the center of a new federal research initiative.

The order calls for the division to be created within an appropriate NIH institute or center and to work with the existing Office of Research on Women's Health. It also establishes a White House Women's Health Task Force co-chaired by Health and Human Services Secretary Robert F. Kennedy Jr. and White House Chief of Staff Susie Wiles.

The administration says the effort will coordinate research and policy across federal agencies. The order identifies maternal health, infertility, endometriosis, uterine fibroids, menopause, heart disease, Alzheimer's disease, stroke, osteoporosis, autoimmune conditions, mental health and chronic pain among the areas requiring greater attention.

Federal agencies are directed to improve the collection and use of sex-specific data, promote the inclusion of women and girls in clinical research and hold grant recipients accountable for considering sex as a biological variable where appropriate. The initiative also seeks to move research findings into clinical care more quickly and use artificial intelligence and other technologies to identify patterns across large health datasets.

The order revokes a 2024 women's health research initiative issued by former President Joe Biden, along with a related 2023 memorandum. The Associated Press reported that the Biden program had attracted nearly $1 billion in federal commitments, according to the previous administration. The White House argues that Trump's replacement is broader and creates stronger coordination through a permanent division and a government-wide task force.

First lady Melania Trump, who has promoted the issue, joined the rollout. The announcement comes two weeks before the Nov. 3 midterm elections, when health care remains a major voter concern. An AP-NORC survey cited by the Associated Press found that women were more likely than men to rank health care among the country's most important issues, while about one-third of women approved of the president's performance.

The political timing does not erase the medical need. For decades, women were underrepresented in important areas of clinical research, and symptoms can present differently across sexes. Conditions that predominantly affect women have also struggled for recognition, research money and timely diagnosis. Better evidence can change treatment guidelines and prevent medical decisions from being built around incomplete data.

The announcement is a starting point, not an outcome

A named division can provide focus, authority and a place where researchers and patients can demand accountability. That is useful. But an organizational chart cannot by itself fund a trial, retain a scientist, recruit a representative group of patients or translate a discovery into care.

The order repeatedly makes its implementation subject to available appropriations. In practical terms, Congress still controls much of the money, and agencies must show how the new structure changes grant decisions. The public should look for measurable commitments: multiyear budgets, transparent research priorities, competitive awards, recruitment targets and timelines for publishing results.

There is also a legitimate question about continuity. The Associated Press noted that earlier administration cuts to scientific work included projects focused on women and that a plan to end the long-running Women's Health Initiative early was reversed after protests. Replacing a previous initiative may be justified if the new system performs better, but discarding useful work merely because it carries another president's name would waste time and public money.

Women's health should not be reduced to a campaign symbol or a partisan possession. Democratic government works best when elected leaders set priorities, Congress funds them, independent scientists test ideas and the public can inspect both the evidence and the spending. Research becomes less trustworthy when political loyalty determines which results are welcomed.

The administration deserves credit for acknowledging that women's health is not a narrow specialty. A woman can face different risks from adolescence through pregnancy, menopause and older age, and those conditions interact with the heart, brain, bones and immune system. Coordinating those fields could reveal patterns that fragmented programs miss.

But the darker pattern in Washington is familiar: leaders celebrate a new office while the difficult work is postponed to future budgets and agencies. Patients do not benefit from a title alone. They benefit when trained researchers have stable support, clinical trials reflect the population and doctors receive reliable evidence they can use.

The new division will therefore be judged less by Monday's ceremony than by what follows. If grants, datasets and treatments improve, the order could become a meaningful correction to a long-standing gap. If funding fails to arrive, it will remain a strong promise without the machinery required to keep it.